Standard BioTools Statistics
Share Statistics
Standard BioTools has 372.26M shares outstanding. The number of shares has increased by 28.31% in one year.
| Shares Outstanding | 372.26M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.3% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 360.48M |
| Failed to Deliver (FTD) Shares | 3.27K |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
The latest short interest is 13.31M, so 3.58% of the outstanding shares have been sold short.
| Short Interest | 13.31M |
| Short % of Shares Out | 3.58% |
| Short % of Float | 3.69% |
| Short Ratio (days to cover) | 7.61 |
Valuation Ratios
The PE ratio is -2.34 and the forward PE ratio is -9.32.
| PE Ratio | -2.34 |
| Forward PE | -9.32 |
| PS Ratio | 1.65 |
| Forward PS | 3.3 |
| PB Ratio | 1.07 |
| P/FCF Ratio | -3.79 |
| PEG Ratio | n/a |
Enterprise Valuation
Standard BioTools Inc. has an Enterprise Value (EV) of 221.45M.
| EV / Earnings | -2.97 |
| EV / Sales | 2.08 |
| EV / EBITDA | -4.07 |
| EV / EBIT | -2.89 |
| EV / FCF | -4.8 |
Financial Position
The company has a current ratio of 1.45, with a Debt / Equity ratio of 0.6.
| Current Ratio | 1.45 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0.6 |
| Total Debt / Capitalization | 37.57 |
| Cash Flow / Debt | -0.44 |
| Interest Coverage | -16.77 |
Financial Efficiency
Return on equity (ROE) is -0.46% and return on capital (ROIC) is -29.48%.
| Return on Equity (ROE) | -0.46% |
| Return on Assets (ROA) | -0.23% |
| Return on Capital (ROIC) | -29.48% |
| Revenue Per Employee | 199.14K |
| Profits Per Employee | -139.81K |
| Employee Count | 534 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 2.72 |
Taxes
| Income Tax | 452.00K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -14.89% in the last 52 weeks. The beta is 1.57, so Standard BioTools 's price volatility has been higher than the market average.
| Beta | 1.57 |
| 52-Week Price Change | -14.89% |
| 50-Day Moving Average | 1.87 |
| 200-Day Moving Average | 2.08 |
| Relative Strength Index (RSI) | 56.8 |
| Average Volume (20 Days) | 1.89M |
Income Statement
In the last 12 months, Standard BioTools had revenue of 106.34M and earned -74.66M in profits. Earnings per share was -0.94.
| Revenue | 106.34M |
| Gross Profit | 50.45M |
| Operating Income | -76.60M |
| Net Income | -74.66M |
| EBITDA | -54.46M |
| EBIT | -76.60M |
| Earnings Per Share (EPS) | -0.94 |
Balance Sheet
The company has 51.70M in cash and 98.21M in debt, giving a net cash position of -46.51M.
| Cash & Cash Equivalents | 51.70M |
| Total Debt | 98.21M |
| Net Cash | -46.51M |
| Retained Earnings | -1.00B |
| Total Assets | 681.54M |
| Working Capital | 332.99M |
Cash Flow
In the last 12 months, operating cash flow was -43.29M and capital expenditures -2.83M, giving a free cash flow of -46.12M.
| Operating Cash Flow | -43.29M |
| Capital Expenditures | -2.83M |
| Free Cash Flow | -46.12M |
| FCF Per Share | -0.58 |
Margins
Gross margin is 47.44%, with operating and profit margins of -72.03% and -70.21%.
| Gross Margin | 47.44% |
| Operating Margin | -72.03% |
| Pretax Margin | -69.78% |
| Profit Margin | -70.21% |
| EBITDA Margin | -51.21% |
| EBIT Margin | -72.03% |
| FCF Margin | -43.37% |
Dividends & Yields
LAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -47% |
| FCF Yield | -6.18% |
Analyst Forecast
The average price target for LAB is $2.88, which is 44% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.88 |
| Price Target Difference | 44% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -0.08 |
| Piotroski F-Score | 3 |